Edecesertib

Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research[1][2][3][4][5].

Product Specifications

CAS Number

[2408839-73-4]

Product Name Alternative

GS-5718

UNSPSC

12352005

Target

IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/edecesertib.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#C[C@@H](C)NC1=C(C(NC[C@@H](F)C(C)(O)C)=O)C=NC(C2=CC=C3N2N=CC(C#N)=C3)=C1

Molecular Formula

C22H22FN7O2

Molecular Weight

435.45

References & Citations

[1]Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.|[2]WHO Drug Information. International Nonproprietary Names for Pharmaceutical|[3]Feng Y, et al. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer[J]. Acta Pharmaceutica Sinica B, 2024.|[4]Kurochkina Y, et al. POS0673 TOLEROGENIC DENDRITIC CELLS IN RHEUMATOID ARTHRITIS PATIENTS: NEWS AND PROMISES[J]. 2021.|[5]Kalliolias GD, et al. Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. Biomedicines. 2024 Jan 9;12 (1) :138.|[6]Ammann S, et al., Pyrrolo[1,2-b] pyridazine derivatives. WO2020014468A1.